US Patent

US11254652 — Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Composition of Matter · Assigned to Agios Pharmaceuticals Inc · Expires 2038-11-21 · 13y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline and amorphous forms of the hemisulfate salt of a compound used to treat conditions associated with pyruvate kinase deficiency.

USPTO Abstract

Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.

Drugs covered by this patent

Patent Metadata

Patent number
US11254652
Jurisdiction
US
Classification
Composition of Matter
Expires
2038-11-21
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.